{"nctId":"NCT01355159","briefTitle":"High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention","startDateStruct":{"date":"2011-04"},"conditions":["Pregnancy Complications","Preeclampsia"],"count":2464,"armGroups":[{"label":"Folic Acid 4 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Folic Acid 4 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Folic Acid 4 mg","otherNames":["Folate"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Capability of subject to comprehend and comply with study requirements\n2. ≥ 18 years of age at time of consent\n3. Subject is taking ≤1.1 mg of folic acid daily at the time of randomization\n4. Live fetus (documented positive fetal heart prior to randomization)\n5. Gestational age between 8+0 and 16+6 weeks of pregnancy (Gestational age (GA) of subjects will be calculated based on the first day of the last menstrual period (LMP) or ultrasound performed before 12+6. If early ultrasound and LMP dates differ by ≤ 7 days, base GA estimate on LMP date; if \\> 7 days, use early \\< 12+6 ultrasound)\n6. Subject plans to give birth in a participating hospital site\n7. Pregnant subjects must fulfill at least one of the following identified risk factors for pre-eclampsia (PE):\n\n   * Pre-existing hypertension (documented evidence of diastolic blood pressure ≥ 90 mmHg on two separate occasions or at least 4 hours apart prior to randomization, or use of antihypertensive medication during this pregnancy specifically for the treatment of hypertension prior to randomization)\n   * Pre-pregnancy diabetes (documented evidence of Type I or type II DM)\n   * Twin pregnancy\n   * Documented evidence of history of PE in a previous pregnancy\n   * BMI \\> 35 kg/m2 within 3 months prior to this pregnancy and up to randomization of this pregnancy (documented evidence of height and weight to calculate BMI is required)\n\nExclusion Criteria:\n\n1. Known history or presence of any clinically significant disease or condition which would be a contraindication to folic acid supplementation of up to 5 mg daily for the duration of pregnancy\n2. Known major fetal anomaly or fetal demise\n3. History of medical complications, including:\n\n   * renal disease with altered renal function,\n   * epilepsy,\n   * cancer, or\n   * use of folic acid antagonists such as valproic acid\n4. Individual who is currently enrolled or has participated in another clinical trial or who received an investigational drug within 3 months of the date of randomization (unless approved by the Trial Coordinating Centre)\n5. Known presence of:\n\n   * Alcohol abuse (≥ 2 drinks per day) or alcohol dependence\n   * Illicit drug/substance use and/or dependence\n6. Known hypersensitivity to folic acid\n7. Multiple Pregnancy (triplets or more)\n8. Participation in this study in a previous pregnancy","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Preeclampsia","description":"PE is defined as diastolic blood pressure ≥90 mmHg on two occasions ≥4 hours apart and proteinuria developed in women greater than 20+0 weeks of gestation. Proteinuria is defined as: urinary protein ≥300mg in 24 hour urine collection OR in the absence of 24 hour collection, ≥2+ dipstick proteinuria, OR random protein-creatinine ratio ≥30mg protein/mmol.\n\nOR HELLP (Haemolysis, Elevated, Liver Enzymes, Low Platelets) syndrome defined as: Haemolysis (characteristic peripheral blood smear), Serum LDH ≥ 600U/L, Serum AST ≥ 70U/L, and Platelet count \\<100 x109/L\n\nOR Superimposed pre-eclampsia, defined as history of pre-existing hypertension (diagnosed pre-pregnancy or before 20+0 weeks' gestation) with new proteinuria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"169","spread":null},{"groupId":"OG001","value":"156","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Death","description":"According to the World Health Organization, \"A maternal death is defined as the death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management but not from accidental or incidental causes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Spontaneous Abortion","description":"Spontaneous abortion or miscarriage defined as death of a fetus \\<500g or \\<20 weeks of gestation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Placenta Abruption","description":"Placental abruption (abruptio placentae) is the premature detachment of a normally positioned placenta from the wall of the uterus.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Premature Rupture of Membranes","description":"Rupture of the membranes (rupture of the amniotic sac) before the onset of labor.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"215","spread":null},{"groupId":"OG001","value":"224","spread":null}]}]}]},{"type":"SECONDARY","title":"Preterm Birth","description":"Birth that occur earlier than 37+0 weeks of gestational age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"297","spread":null},{"groupId":"OG001","value":"304","spread":null}]}]}]},{"type":"SECONDARY","title":"HELLP (Hemolysis, Elevated Liver Enzyme Levels & Low Platelet Count)","description":"Haemolysis (characteristic peripheral blood smear), Serum LDH \\>=600U/L, Serum AST \\>=70U/L, Platelet count \\<100 x109/L","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Severe Preeclampsia","description":"Severe PE: Defined as PE with convulsion or HELLP or delivery \\<34 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Antenatal Inpatient Length of Stay","description":"Length of inpatient stay before admission for delivery in days","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"7.7"},{"groupId":"OG001","value":"5.2","spread":"6.2"}]}]}]},{"type":"SECONDARY","title":"Stillbirth","description":"Fetal death defined as death of fetus of at least 500 grams birth weight or, if birth weight is unavailable, a gestational age of at least 20+0 weeks of gestation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Intrauterine Growth Restriction (<3rd Percentile)","description":"Intrauterine growth restriction is defined as a birth weight less than the 3rd percentile of the population, adjusted for sex and gestational age, based on the current population-based Canadian reference standard.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Intrauterine Growth Restriction (<10th Percentile)","description":"Intrauterine growth restriction is defined as a birth weight less than the 10th percentile of the population, adjusted for sex and gestational age, based on the current population-based Canadian reference standard.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"144","spread":null}]}]}]},{"type":"SECONDARY","title":"Neonatal Death","description":"Neonatal death defined as death of a baby that occurred during first 28 days of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Perinatal Mortality","description":"The perinatal mortality is defined as the number of deaths (fetal deaths and neonatal deaths) of babies ≥ 500 grams birth weight or, if birth weight is unavailable, a gestational age ≥ 20+0 weeks, up to 28 completed days after birth.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Retinopathy of Prematurity","description":"Retinopathy of prematurity a retinopathy typically occurring in premature infants treated with high concentrations of oxygen, characterized by vascular dilatation, proliferation, tortuosity, edema, retinal detachment, and fibrous tissue behind the lens confirmed by retinal examination according to an International Committee for the Classification of Retinopathy of Prematurity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Onset Sepsis","description":"Within first 48hr of life, confirmed by positive blood or cerebrospinal fluid cultures","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Necrotising Enterocolitis","description":"Necrotizing enterocolitis (NEC) according to modified Bell's criteria stage 2 or higher (grossly bloody stool, plus absent bowel sounds with or without abdominal tenderness and radiographic findings such as intestinal dilation, ileus, pneumatosis intestinalis), excluding isolated spontaneous intestinal perforations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Intraventricular Hemorrhage (IVH)","description":"* IVH Grade 1(Blood in germinal matrix)\n* IVH Grade 2 (Blood in germinal matrix and extending into the ventricles)\n* IVH Grade 3 (Ventricular enlargement)\n* IVH Grade 4 (Intraparenchymal lesion)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Ventilation","description":"Ventilatory support after initial resuscitation, with/without intubation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Need for Oxygen at 28 Days","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite Severe Adverse Fetal/Neonatal Outcome","description":"Composite outcome included any of retinopathy of prematurity, periventricular leukomacia, early onset sepsis, necrotizing enterocolitis, intraventricular haemorrhage, ventilation. Need for O2at 28 days, NICU admission","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Length of Stay in 'High Level' Neonatal Care Unit","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":"27"},{"groupId":"OG001","value":"17","spread":"23"}]}]}]},{"type":"SECONDARY","title":"Neonatal Death","description":"Neonatal death defined as death of the infant occurred before 28 days of life","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"144","spread":null}]}]}]},{"type":"SECONDARY","title":"Periventricular Leukomalacia","description":"One of the two outcomes used to measure neonatal morbidity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Neonatal Intensive Care Unit (NICU) Admission","description":"This outcome measured whether or not the infant was admitted into the NICU.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"299","spread":null},{"groupId":"OG001","value":"267","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":227,"n":1227},"commonTop":["Other AE"]}}}